Navigation Links
Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Date:11/4/2009

Alzheimer's disease that will evaluate as primary endpoints the effects of adding dimebon to Namenda®, a standard of care Alzheimer's disease medicine, on cognitive and behavioral symptoms.
  • Initiated patient enrollment in CONTACT, a six-month, randomized, double-blind, placebo-controlled Phase 3 trial in approximately 600 patients with moderate-to-severe Alzheimer's disease that will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with Aricept®, the leading Alzheimer's medication worldwide, on neuropsychiatric symptoms and activities of daily living. This study is the first pivotal Alzheimer's disease study to use the Neuropsychiatric Inventory (NPI) scale as a co-primary endpoint.
  • Continued patient enrollment in CONCERT, a 12-month Phase 3 clinical trial in patients with mild-to-moderate Alzheimer's disease that is designed to evaluate the efficacy of dimebon when added to ongoing treatment with Aricept.
  • Continued patient enrollment in HORIZON, a six-month, double-blind, placebo-controlled Phase 3 trial that is evaluating dimebon's potential benefits on cognition in patients with Huntington disease.

    • *Latrepirdine is the proposed generic name for dimebon.

    MDV3100

    • Entered into a global collaboration agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for the treatment of prostate cancer. Under the terms of the agreement, Medivation has received an up-front cash payment of $110 million and is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones, plus up to an additional $320 million in commercial milestone payments.
    • Initiated AFFIRM, a randomized, placebo-controlled, double-blind Phase 3 survival trial that is evaluating 160 mg/day of MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel
      '/>"/>

    SOURCE Medivation, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
    2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
    3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
    4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
    5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
    6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
    7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
    8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
    9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
    10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
    11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/16/2009)... GREEN BAY, Wis., Dec. 16 ... DolCas Biotech for the use of super ... in multiple EuroPharma formulations. The exclusive ... both the health food store channel and ... naturopathic doctors, and clinics. BCM-95® is ...
    (Date:12/16/2009)... -- RealMed has been ranked the #1 ... 2009 Top 20 Best in KLAS Awards: ... is a dynamic revenue cycle management solution ... healthcare providers and all payers. ... in vendor performance measurement in the software, ...
    (Date:12/16/2009)... Pa., Dec. 16 Siemens ... financing solutions to ... and meet deadlines defined within the HITECH ... Act (ARRA). Featuring zero-percent interest ... organizations to defer up-front payments associated with ...
    Breaking Medicine Technology:EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4The 2009 James Irvine Foundation Leadership Awards Honor Extraordinary Californians for Innovative Practical Solutions 48326 1The 2009 James Irvine Foundation Leadership Awards Honor Extraordinary Californians for Innovative Practical Solutions 48326 2The 2009 James Irvine Foundation Leadership Awards Honor Extraordinary Californians for Innovative Practical Solutions 48326 3The 2009 James Irvine Foundation Leadership Awards Honor Extraordinary Californians for Innovative Practical Solutions 48326 4The 2009 James Irvine Foundation Leadership Awards Honor Extraordinary Californians for Innovative Practical Solutions 48326 5Medical Transcription Services Provider MxSecure to Host Free Webinar 3A 26apos 3BThe Future of Patient Documentation 26apos 3B 48323 1Medical Transcription Services Provider MxSecure to Host Free Webinar 3A 26apos 3BThe Future of Patient Documentation 26apos 3B 48323 2Medical Transcription Services Provider MxSecure to Host Free Webinar 3A 26apos 3BThe Future of Patient Documentation 26apos 3B 48323 3NBAs Ronny Turiaf Joins Forces with Heart Group to Promote Heart Health 48320 1NBAs Ronny Turiaf Joins Forces with Heart Group to Promote Heart Health 48320 2
    ... TSI Health Sciences to ... ... TSI Health,Sciences, a well-respected $50 million dietary supplement industry,ingredients supplier ... drawn into a wide-spread quality issue with the,company,s primary Chinese ...
    ... EDAP TMS S.A. (Nasdaq:,EDAP), the global leader in ... is currently conducting clinical,investigations in France under an ... chemotherapy using docetaxel. The study is a ... localized but aggressive high risk prostate cancer typically,classified ...
    Other Medicine Technology:Tainted Chinese Food Ingredients First Discovered in 2005 2Tainted Chinese Food Ingredients First Discovered in 2005 3Tainted Chinese Food Ingredients First Discovered in 2005 4Tainted Chinese Food Ingredients First Discovered in 2005 5EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer 2EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer 3
    (Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...
    (Date:12/16/2009)... though, that no direct link has been found, , , ... in food -- commonly linked to food poisoning and ... also be the cause of some urinary tract infections. ... bacteria in chicken from stores and restaurants and in ... that the germs were transmitted directly to the women ...
    (Date:12/16/2009)... Specific Neurological Stress Reduction Therapy or NSRTSM is found very ... conditions such as allergies, asthma, migraines, chronic fatigue and a ... throughout the country are using this holistic therapy including over ... ... Minneapolis, MN (Vocus) December 14, 2009 -- ...
    (Date:12/16/2009)... Age should not be determining factor for use, expert ... people with heart failure are much less likely to ... a new study. , The study included 4,685 people, ... device and had a left ventricular fraction (a measure ... less. , During a three-year period, those who were ...
    (Date:12/16/2009)... government report shows, , , WEDNESDAY, Dec. 16 (HealthDay News) ... reached almost 78 years, a record high, federal health ... can expect to live to 80.4 years on average ... from the U.S. Centers for Disease Control and Prevention. ... live longer than their parents, life expectancy in the ...
    Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Implanted Defibrillator Might Extend Life 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3
    ... Cant smell the roses? Maybe youre depressed. Smell too ... same problem. Scientists from Tel Aviv University recently linked ... glands. It might explain why some women, without realizing ... that supports this theory was published this year in ...
    ... FOR JAN. 23, 2008, SAN FRANCISCO, Jan. 3 ... Foundation (GRF) will,commemorate its 30th Anniversary with a gala ... Francisco, Jan. 23, 2008. The annual event,"Speeding the Cure. ... in GRF-funded research., Glaucoma is the leading cause ...
    ... MDTH ) announced that its senior management will ... held January,7 - 10, 2008 at the Westin St. ... will give its presentation on Thursday,January 10, 2008 at ... over the Internet via MedCath,s website (http://www.medcath.com ) ...
    ... strategy, CLEVELAND, Jan. 2 PolyOne ... specialized polymer materials, services,and solutions, announced today ... GLS Corporation, the leading North American provider ... and medical,applications., This acquisition complements PolyOne,s ...
    ... Her Rape Accusation, LOS ANGELES, Jan. 3 ... regarding her lawsuit against,Esai Morales:, ... coming out today. I. Background, My name ... company called,Critical Mass Entertainment Group. Critical Mass provides strategic,marketing, ...
    ... risks , , WEDNESDAY, Jan. 2 (HealthDay News) -- The ... pressure in patients with kidney cancer, French researchers report. ... published last month that found the drug increased blood ... with stomach cancer. , "Patients taking sunitinib and other ...
    Other Medicine News:Health News:Why some depressed girls can't smell the roses 2Health News:January is National Glaucoma Awareness Month 2Health News:PolyOne Completes Acquisition of GLS Corporation 2Health News:PolyOne Completes Acquisition of GLS Corporation 3Health News:PolyOne Completes Acquisition of GLS Corporation 4Health News:Transcript of Elizabeth Mazzocchi Press Conference 2Health News:Transcript of Elizabeth Mazzocchi Press Conference 3Health News:Transcript of Elizabeth Mazzocchi Press Conference 4Health News:Transcript of Elizabeth Mazzocchi Press Conference 5Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3
    ... Collection Tubes are 100% plastic capillary blood ... of applications, the Capillary Collection Tubes are ... and a micro tube.,The capillary tube uses ... the micro tube thereby eliminating the tendency ...
    ... an enzyme immunoassay test in a microwell format. ... incubation. The results are objective and normalized ... The Bio-Rad Mumps IgG test is intended for ... antibodies to mumps virus in human serum by ...
    ... for Toxoplasmosis has progressed from ... dye test to immunoflourescence, latex ... In addition to Toxo ... both Toxo IgM immunocapture and ...
    ... is a safe, effective and relatively bloodless ... It is easy to learn and can ... in an outpatient setting with few if ... the procedure, minimize OR time and use ...
    Medicine Products: